FDA authorizes Novavax’s COVID-19 vaccine for adolescents ages 12 to 17

CNN (8/19, Howard) reported the FDA “authorized Novavax’s COVID-19 vaccine on Friday for emergency use in adolescents.” Novavax’s protein-based “vaccine was authorized for adults in July,” and with this “latest emergency use authorization, it also will be available as a two-dose primary series for ages 12 to 17.” In the “age group, ‘overall, the clinical efficacy of the vaccine is around 80%,’ said” Novavax Global Corporate Affairs Senior Vice President Silvia Taylor.

Source: https://us.cnn.com/2022/08/19/health/novavax-covid-vaccine-adolescents/index.html